This new distinct pathway of CRC is characterized by activating mutation of the BRAF proto-oncogene (specifically V600E) and widespread and concordant gene promoter hypermethylation (CpG Island methylation Phenotype or CIMP) [5]–[8], and is responsible for silencing of many genes by CpG island methylation in specific cancer subtypes [9]. The gene discussed is BRAF; the disease is cancer.